Amarin, after 33% revenue decline, aims to 'stabilize' US sales and grow in Europe

After Amarin lost U.S. patent protections for its sole drug Vascepa, the company embarked on cost cuts and shifted to a digital-first marketing strategy. Now, the company aims to "stabilize" U.S. sales and grow its presence in Europe, execs said Wednesday.